Otsuka

Pharma

Lilly-InnoCare, Elevar, China's 5-year plan—Fierce Pharma Asia

Lilly and InnoCare inked a potential $3.35 billion deal. The FDA approved a novel cancer drug in a first for Korea. China set an ambitious five-year plan.

Angus Liu Sep 25, 2026 9:38am

drug recall FDA recall recall voluntary recall

Otsuka venture yanks sodium chloride for IV over labeling issue

Sep 24, 2026 9:41am

Vera’s strong ph. 3 Trutakna data intensify IgAN rivalry

Sep 16, 2026 2:50pm

Takeda, Daiichi, Astellas and more—Fierce Pharma Asia

Aug 7, 2026 8:35am

In a first, Otsuka’s Voyxact stabilizes IgAN kidney loss in ph.3

Aug 3, 2026 5:00pm

Legend Biotech, Merck, Otsuka—Fierce Pharma Asia

Jul 31, 2026 9:00am